We have located links that may give you full text access.
Long noncoding RNA SPRY4-IT1 is a prognostic factor for poor overall survival and has an oncogenic role in glioma.
OBJECTIVE: Long non-coding RNAs (lncRNAs) are emerging as biomarkers and as important regulators of the biological processes and tumorigenesis in cancer. The purpose of this study is to investigate the clinical significance of lncRNA SPRY4-IT1 in glioma.
PATIENTS AND METHODS: The expression level of SPRY4-IT1 was examined by the quantitative Real-time PCR (qRT-PCR) in glioma tissues and control tissues and its association with overall survival of patients was analyzed by statistical analysis. Survival curves were made using the Kaplan-Meier method, and the log-rank test was used to analyze the differences between clinicopathological characteristics and survival in glioma patients.
RESULTS: The expression level of SPRY4-IT1 was significantly higher in glioma in comparison to normal matched tissue (p < 0.01). Furthermore, lncRNA SPRY4-IT1 was associated significantly with WHO grade (p = 0.009) and tumor size (p = 0.003). A significant difference was found that glioma patients with high SPRY4-IT1 expression level had distinctly shorter OS than patients with low SPRY4-IT1 expression level. Furthermore, Multivariate analysis indicated SPRY4-IT1 as an independent prognostic indicator for glioma patients (p = 0.003), CONCLUSIONS: The lncRNA SPRY4-IT1 may be a potential prognostic bio¬marker of glioma.
PATIENTS AND METHODS: The expression level of SPRY4-IT1 was examined by the quantitative Real-time PCR (qRT-PCR) in glioma tissues and control tissues and its association with overall survival of patients was analyzed by statistical analysis. Survival curves were made using the Kaplan-Meier method, and the log-rank test was used to analyze the differences between clinicopathological characteristics and survival in glioma patients.
RESULTS: The expression level of SPRY4-IT1 was significantly higher in glioma in comparison to normal matched tissue (p < 0.01). Furthermore, lncRNA SPRY4-IT1 was associated significantly with WHO grade (p = 0.009) and tumor size (p = 0.003). A significant difference was found that glioma patients with high SPRY4-IT1 expression level had distinctly shorter OS than patients with low SPRY4-IT1 expression level. Furthermore, Multivariate analysis indicated SPRY4-IT1 as an independent prognostic indicator for glioma patients (p = 0.003), CONCLUSIONS: The lncRNA SPRY4-IT1 may be a potential prognostic bio¬marker of glioma.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app